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Essay
Informed Consent in the Genomics Era
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S
ince the Nuremberg trials, 
informed consent (IC) has been 
recognized as a basic ethical 
requirement for research involving 
human participants [1] (Table 1). 
Such consent encompasses two 
distinct elements: (1) researchers 
communicate detailed information 
about study procedures, outcomes, 
risks, and benefits for the participating 
individual or community, and (2) 
after understanding and careful 
consideration, the participants consent 
to take part under these conditions. 
However, the suitability of IC for 
genomic studies has been recently 
challenged [2,3]. Because the research 
protocol for such studies may evolve 
over time, the condition in IC of 
providing detailed information for 
a well-defined protocol is not easily 
satisfied.
Large amounts of data stored as 
electronic records allow multiple post-
hoc analyses, which in many cases 
were not foreseen at the beginning 
of a study. The potential for analysis 
is constantly growing and recently 
has increased dramatically with the 
development of high-throughput 
sequencing and genotyping 
technologies. More than one million 
genetic variants of an individual may 
be determined within hours—and 
even the full genetic sequence 
within weeks [3]. Such technical 
advances expose participants to a 
new class of risk different from the 
physical harm usually considered 
in ethical reviews [4,5]. Release of 
genetic information could lead to 
uninsurability, unemployability, 
discrimination, and the breakdown of 
family relationships by unintentionally 
demonstrating missing or unknown 
relatedness. Moreover, participants 
usually do not get any direct benefit 
from the research. All of these 
concerns raise the question: are IC 
procedures still in accordance with the 
currently accepted ethical standards 
of autonomy, beneficence, and non-
maleficence?
There is pressure to harmonize 
different views, since a shared ethical 
and legal framework is still missing 
and approaches vary greatly [6–8]. 
A wide spectrum of opinions exists: 
Some researchers believe that available 
sample collections do not need 
any further consent, even for large-
scale genotyping [9], while some 
institutional review boards recommend 
the destruction of samples immediately 
after testing (MW, personal 
observation).
Unfortunately, in current practice, 
the only moment when a person is 
really able to make a choice about 
participating in clinical research is 
when they sign the IC form. At this 
moment, the balance of power between 
overall research goals and individual 
interests should find equilibrium. As 
a study participant, however, one also 
has the right to know who owns the 
data, who guarantees proper handling, 
who will have further access to the 
data, and what security measures are 
in place. And all these concerns arise 
against a background in which the 
research questions themselves may 
rapidly change with the advancement of 
technical knowledge [10]. Any further 
genetic analysis may in fact severely 
compromise individual interests and 
autonomous choice, particularly if the 
individual is not fully aware of the very 
nature of the generated data and the 
implications of its use (or potential 
abuse). A stepwise informed consent 
should therefore be considered in 
accordance with the Council for 
International Organizations of Medical 
Sciences guidelines, one of the first to 
define IC not as a finite time step, but 
as an ongoing process [11] (Figure 
1). Also, UNESCO’s International 
Declaration on Human Genetic Data 
states that “clear, balanced, adequate 
and appropriate information shall be 
provided to the person whose prior, 
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biological materials hold great 
promise for medical research, but 
also present new problems that are 
profoundly different from the classical 
clinical trial for which informed 
consent was developed. 
sÈ 4HEÈCLASSICALÈRISKBENEFITÈANALYSISÈ
of physical harm doesn’t take 
into account new threats to the 
individual such as uninsurability, 
unemployability, genetic 
discrimination, or disruption of family 
relationships.
sÈ 4RADITIONALÈINFORMEDÈCONSENTÈMAYÈ
therefore no longer be appropriate 
when dealing with long-term studies 
using biological materials.
sÈ )NFORMEDÈCONSENTÈSHOULDÈBEÈSEENÈ
as an ongoing process between 
researcher and participant, and not 
just as a once-and-for-all decision.
sÈ 2ESEARCHÈFOLLOWINGÈTHEÈINITIALÈSTORAGEÈ
of samples needs to be likewise 
explained and may be announced 
using new communication methods.
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free, informed and express consent 
is sought” [12]. This goal seems to be 
largely in contrast with procedures in 
current genomic studies. Since this kind 
of detailed information is difficult to 
provide, a frequently favored approach 
is to ask for a broad consent [13]. 
But a more detailed analysis of the 
rationale behind broad consent shows 
that “broad consent” is seldom if ever 
justified [14]. Although proponents of 
“broad consent” argue that individuals 
will maintain a right to withdraw from 
the study, this right seems to be more 
of a fig leaf than a true option. As 
the value of stored samples increases 
over time due to additional data 
being generated, a later withdrawal of 
consent is difficult; it would require 
not only removal of printed lists and 
questionnaires but also deletion of 
current computer files including 
backups as well as all samples and 
aliquots.
Therefore the Council for 
International Organizations of Medical 
Sciences guidelines recommend 
broad consent be sought only 
under certain circumstances [11]. 
Such circumstances include (1) 
obtaining the approval of an ethical 
committee and (2) keeping data and 
samples anonymous. Anonymity, 
however, is in practice impossible 
to guarantee [15,16]. Genetic data 
are intrinsically self-identifying, 
hence their use in criminal forensic 
investigations [17]. Advances in 
computer science allow cross-matching 
Table 1. History: From an Early Informed Consent Proposal to Modern Recommendations for Genetic Studies
Guidelines and Laws Years Source
Nuremberg Code (http://ohsr.od.nih.gov/guidelines/nuremberg.html) 1947 A first generally accepted code of ethics in medical 
research
Declaration of Helsinki (http://www.wma.net/e/policy/b3.htm) 1964, 1975, 1983, 1989, 2000, 2002, 2004; 
next amendment October 2008
Guidelines by the World Medical Association
Belmont Report (http://ohsr.od.nih.gov/guidelines/belmont.html) 1973 US government regulations
International Ethical Guidelines for Biomedical Research (http://www.
cioms.ch/frame_guidelines_nov_2002.htm)
1982, 1993, 2002 World Health Organization and Council for International 
Organizations of Medical Sciences
Statement on the Principled Conduct of Genetics Research (http://
www.eubios.info/HUGO.htm)
1996 Human Genome Organisation Ethical, Legal and Social 
Issues Committee
Convention on Human Rights and Biomedicine (http://conventions.
coe.int/Treaty/Commun/QueVoulezVous.asp?NT=164&CL=ENG)
1997 Council of Europe
Universal Declaration on the Human Genome and Human Rights 
(http://portal.unesco.org/shs/en/ev.php-URL_ID=1881&URL_DO=DO_
TOPIC&URL_SECTION=201.html)
1997 UNESCO’s 29th General Conference
Genomics and World Health (http://whqlibdoc.who.int/hq/2002/
a74580.pdf)
2002 World Health Organization
International Declaration on Human Genetic Data [12] 2003 UNESCO
Pharmacogenetics: Ethical Issues (http://www.nuffieldbioethics.org/
go/ourwork/pharmacogenetics/publication_314.html)
2003 Nuffield Council of Bioethics
Human Tissue Act (http://www.opsi.gov.uk/acts/acts2004/
ukpga_20040030_en_1)
2004 UK framework for use of organs and tissue
Ethical, Legal and Social Aspects of Genetic Testing: Research, 
Development and Clinical Applications (http://ec.europa.eu/research/
conferences/2004/genetic/pdf/report_en.pdf)
2004 Report for the European commision
Setting Standards of Quality and Safety for the Donation, Procurement, 
Testing, Processing, Preservation, Storage and Distribution of Human 
Tissues and Cells (http://eur-lex.europa.eu/LexUriServ/LexUriServ.
do?uri=OJ:L:2006:038:0040:01:EN:HTML)
2004 European parliament and of the council (directive 
2004/23/EC )




25 Recommendations on the Ethical, Legal and Social Implications 
of Genetic Testing (http://ec.europa.eu/research/conferences/2004/
genetic/recommendations_en.htm)
2004 European Commission
Universal Declaration on Bioethics and Human Rights (http://portal.
unesco.org/shs/en/ev.php-URL_ID=1883&URL_DO=DO_TOPIC&URL_
SECTION=201.html)
2005 World Health Organization
DRAFT International Ethical Guidelines for Epidemiological Studies 
(http://www.cioms.ch/080221feb_2008.pdf)
2008 World Health Organization and Council for International 
Organizations of Medical Sciences
Genetic Information Nondiscrimination Act (http://www.genome.
gov/24519851)
2008 United States of America
DRAFT Additional Protocol to the Convention on Human Rights and 
Biomedicine, concerning Genetic Testing for Health Purposes (http://
assembly.coe.int/Main.asp?link=/Documents/WorkingDocs/Doc07/
EDOC11466.htm)
2008 Council of Europe
Guidelines for Human Biobanks and Genetic Research Databases 
(http://www.oecd.org/document/12/0,3343,en_2649_34537_
40302092_1_1_1_1,00.html)
2008 (under public scrutiny) Organisation for Economic Co-operation and 
Development
Adapted from [25].
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of data not previously foreseen, as 
shown in the “Netflix” affair (http://
www.nytimes.com/2007/06/04/
technology/04netflix.htm). With every 
bit of additional data, anonymity is 
decreasing, in particular when genetic 
testing may be used to reconstruct 
ethnicity, sex, age, height, and other 
body characteristics such as eye and 
hair color [18]. Unfortunately, nobody 
can foresee the implications of these 
threats to genetic privacy. With the 
stability of DNA and its potential for 
use even with only trace amounts, 
genomics studies will have an almost 
infinite duration if not actively 
terminated. Moreover, any genetic 
variant determined in someone’s 
DNA will have a good chance of also 
being present in that person’s children 
(who may have never consented to the 
analysis of their genome in the first 
place). Hence there is a community 
dimension to IC for genomic studies, 
especially when combined with 
genealogical data. 
There is substantial uncertainty 
in the development of genomics 
projects that may arise, which cannot 
be foreseen even by institutional 
review boards. Moreover, many 
researchers in the field currently 
see their institutional review board 
only as an “obstacle course” with an 
uncertain outcome [19]. With many 
issues now arising in the interplay 
between research-driven interests, 
new discoveries, and society, such as 
allocation of research resources, data 
ownership, and publication of results, 
the problem is not so much the 
doctrine of IC but its implementation 
[20]. Most if not all of the problems 
could certainly be addressed by 
a better researcher–participant 
relationship [21]. As Veatch notes: 
“In the past, research subjects have 
all too often been treated as passive 
“material” suitable for providing 
additional data points…[while] 
partners normally come together not 
because they share exactly the same 
interests or abilities, but because there 
is some mutuality of interests, some 
common point of intersection where 
each can help the other” [21]. A 
research partnership will demonstrate 
not only the potential benefits of 
such research, but also the current 
difficulties that need to be addressed. 
Reassuring research participants 
that anonymity will be preserved just 
to avoid a deeper discussion about 
the issues involved in genomics 
research may undermine the trust 
and collaborative spirit that is needed 
between science and society.
In current genomic studies, the 
relationship between researcher and 
participant may be different from the 
traditional physician–patient studies. 
Most of the research staff in current 
genomics projects will not have any 
direct contact with participants. In 
addition, these studies are usually not 
expected to give any direct benefit to 
the participants, as they are not seeking 
any new treatment. These two features 
of genomics research need to be 
reflected in the partnership between all 
actors involved in the research. Where 
possible, participants should be actively 
involved in information exchange and 
the decision-making process [3,18]. 
Several authors have already suggested 
an exploratory or participatory process 
prior to the implementation of a 
research project that should provide 
a better understanding of relevant 
issues through interest groups, 
consensus conferences, meetings, 
or surveys [10,16,20]. We propose 
a circular process of information 
exchange (Figure 1). Following a first 
phase of general information, a more 
detailed information exchange then 
takes place. IC in this context should 
be defined as an ongoing process 
instead of a once-and-for-all-time 
decision [22]. Understanding IC as 
Box 1: An Implementation Plan
Carefully inform the community about the planned study
Collect feedback and take it into account for policy changes
Redesign informed consent forms so that consent may be initially given only for 
interview, physical examination, data, and sample storage
Explain terms without ambiguity (for instance, explain that anonymity may be limited 
even with anonymized samples)
Explain opt-in/opt-out procedures for further genetic testing
Establish conventional communication channels (face-to-face or group meetings, 
letters) but also use electronic communications (e-mail alerts, Web sites, RSS feeds, 
electronic voting, blogs, chat rooms, social platforms)
Offer freephone number, SMS broadcasts
Develop transparent annotation rules for individual genetic data
Respect the right to know and the right not to know
Adjust protocols to local needs and individual wishes
doi:10.1371/journal.pmed.0050192.g001
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a process will furthermore bring the 
“community dimension” back into 
focus. In addition to communicating 
the impact of the results together with 
the hope that these may bring forth 
improved diagnostics, personalized 
medicine, prevention, and health care, 
the circular IC process would also 
provide an opportunity to examine the 
difficulties and challenges raised by 
such research. 
Kohane and colleagues have 
argued that the recent advances of 
information technology can further 
help in an ethical decision-making 
process [23]. At least in industrialized 
countries, such technology now 
allows the establishment of dynamic 
participant–researcher partnerships. 
In the past, contacting participants 
after a study was over would have 
been prohibitively expensive, but such 
contacts can now be easily managed 
by serialized SMS, e-mail, or regularly 
updated Web pages, with letters for 
those without Internet or mobile 
phone access (Box 1). Newsletters, 
public meetings, or local newspaper 
articles may also be considered as a 
channel to communicate research 
results. Participants may decide if 
they are willing to answer further 
questions, undergo additional tests, 
and give permission for their specimens 
to be included in a future series of 
genotyping, expression profiling, or 
proteomic analyses [24].
We are aware that implementing 
our suggested process of ongoing IC 
may require additional efforts, but we 
believe that our approach will lead to a 
better understanding and a new level of 
transparency in research. Reorienting 
IC in the genomics age as a circular 
process of communication involving 
researchers and participants as 
partners in an open dialogue is a great 
opportunity to build trust between 
science and society, while giving new 
force and meaning to the ethics of 
research.  
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